The company is outgrowing its own explanations: management keeps telling investors the reported numbers are not the busi
The model's full reasoning — Q4 2021 call → NOWe need to determine if management conveys that the reported results do not represent the business as it is actually running today, i.e., that the business has moved beyond what the numbers show. We need to look for management's own words indicating a gap between the reported period and current state, grounded in real activities, not just future plans. Let's review the transcript. Key points: - Jurgi speaks about 2021 as transformative, but focuses on strategic pillars. - They discuss Q4 results and guidance for 2022. - There's mention of new product launches like HRD, CarePath, DEEP-Lung-IV study. - Important: They emphasize strong momentum, customer adoption, utilization, etc. - Peter Casasanto talks about biopharma opportunities. - Ross Muken discusses financial results, guidance. - Q&A: They discuss deal activity, large customers, U.S. expansion, etc. Do they say that the reported results are stale relative to the current business? For example, do they say that the quarter didn't include some new business that's now in effect? Or that the business is running at a higher level now? Look for phrases like "we have seen unprecedented activity" or "we are running ahead" or "the quarter didn't capture the recent wins" etc. In the prepared remarks, they talk about 2021 as a strong year. They give guidance for 2022. They talk about new products. But they don't explicitly say "the reported numbers are behind where we are now" in a substantial way. In Q&A, Tejas asks about the guide, and Ross says they are conservative. They mention backlog, bookings momentum, utilization trends. But they don't say the reported period understates the current business. Jurgi says about Q4: "We maintain momentum" etc. They mention that they are expecting several signed agreements with Tier 1 institutions in the coming months. That's future. They say about HRD: "We do see a lot of demand" but that's not necessarily current revenue. They talk about DEEP-Lung-IV study: 16 sites signed up. That's ongoing, but clinical study not yet revenue. They talk about Ambry Genetics LOI - that's future. In Q&A, they mention "unprecedented activity with very large customers" and "size of certain RFPs or quotes are much bigger than what we have seen in the past" - that's about pipeline, not current revenue.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| KOPN | Kopin Corporation | Q4 2023 | 2024-03-14 | C+ |
| PFE | Pfizer Inc. | Q4 2023 | 2024-01-30 | F |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| NBTX | Nanobiotix S.A. | Q2 2023 | 2023-09-27 | D |
| PRPH | ProPhase Labs, Inc. | Q1 2023 | 2023-05-11 | F |
| VRE | Veris Residential, Inc. | Q4 2022 | 2023-02-22 | D |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| LIND | Lindblad Expeditions Holdings, Inc. | Q2 2017 | 2017-08-06 | C |
VRE · Q4 2022 → YESThe question is: Does management convey that the reported results for the period do not represent the business the company is actually running today? That the just-reported numbers describe a company ...YES The transcript shows management repeatedly framing the reported period as transitional and not reflective of the current business: the shift to a pure-play multi-family company has already reduced office and hotel exposure while driving multi-family NOI share to 98%, with Haus25 leased at 95% ahead of schedule and same-store NOI guidance of 4-6% for 2023. They explicitly note that earnings variability stems from the ongoing asset sales and reallocation, with the business now positioned for growth as the transformation concludes, and they highlight post-period activity like additional sales and stabilized properties to underscore that the reported numbers capture a pre-transition state.
PFE · Q4 2023 → YESThe question is: Does management convey that the reported results do not represent the business the company is actually running today? That the just-reported numbers describe a company that has alread...NO The transcript shows management framing 2023 results as a challenging year with declines driven by COVID products, while positioning 2024 as a year of execution and growth through new priorities like the Seagen acquisition (closed late in 2023 with minimal contribution) and new product launches. This is a standard results-and 2024 outlook discussion, with forward-looking elements on pipeline, margins, and capital allocation rather than indicating the reported period is stale relative to current operations.
PRIM · Q2 2018 → YESThe question is whether management conveys that the reported results for Q2 2018 do not represent the business the company is actually running today. Specifically, if the printed period is stale relat...YES The transcript shows management repeatedly framing the Q2 results as a partial picture due to the late June 1 acquisition of Willbros. They note the business is "running as planned," highlight one-month revenue contribution of $1.